Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 17,822 shares at $27.69 ($494K) on 2024-11-15, disclosed to the SEC on 2024-11-19.
Scheduled sale ($494k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $27.69 | 8,761 | $243K | 49.1% |
| 2 | $27.69 | 8,761 | $243K | 49.1% |
| 3 | $28.82 | 300 | $9K | 1.8% |
| Total | $27.71 avg | 17,822 | $494K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |